Lonza’s Pharma&Biotech vision is to enable our customers to meet some of the greatest challenges in patient treatment. The Pharma&Biotech market-focused segment is comprised of the following businesses:
- Mammalian Manufacturing
- Chemical and Microbial Manufacturing
- Clinical Development and Licensing
- Emerging Technologies
- Bioscience Solutions
Pharma&Biotech Overview 2016
Our Pharma&Biotech segment delivered remarkable sales growth of 15.9% (15.8% in constant exchange rates), reaching CHF 1.85 billion, which led to an exceptional CORE EBIT of CHF 400 million and an extremely high 40.8% CORE EBIT growth year-over-year.
This outstanding performance was driven by commercial excellence and strong operational execution. The strong momentum in Mammalian Manufacturing was complemented by a significant upward trend in all other technologies and modalities. Furthermore, our continued cost and manufacturing discipline helped the segment achieve these remarkable results. Our strong regulatory track record continued with 154 successful regulatory and customer audits.
During 2016 Lonza’s Pharma&Biotech segment announced several long-term, strategic manufacturing agreements, such as with Kodiak Sciences, bluebird bio and Clovis Oncology.
In the year ahead, Lonza’s Pharma&Biotech will focus on strengthening our core offering to deliver further operational and commercial excellence.
Pharma&Biotech Financial Summary
|million CHF||2016||Change in %||2015|
|CORE EBIT margin in %||21.6||17.8|
|CORE EBITDA margin in %||28.7||26.2|